620 related articles for article (PubMed ID: 29733389)
41. Antioxidant responses related to temozolomide resistance in glioblastoma.
Campos-Sandoval JA; Gómez-García MC; Santos-Jiménez JL; Matés JM; Alonso FJ; Márquez J
Neurochem Int; 2021 Oct; 149():105136. PubMed ID: 34274381
[TBL] [Abstract][Full Text] [Related]
42. [Glioblastoma That Does Not Improve with Standard Treatment: Poor Prognostic Factors and Future Perspectives].
Narita Y
Brain Nerve; 2022 May; 74(5):668-676. PubMed ID: 35589662
[TBL] [Abstract][Full Text] [Related]
43. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
44. Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Nagasawa DT; Chow F; Yew A; Kim W; Cremer N; Yang I
Neurosurg Clin N Am; 2012 Apr; 23(2):307-22, ix. PubMed ID: 22440874
[TBL] [Abstract][Full Text] [Related]
45. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
Yang B; Ma YB; Chu SH
Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
[TBL] [Abstract][Full Text] [Related]
46. Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide.
Ebrahimi Zade A; Shahabi Haghighi S; Soltani M
Comput Methods Programs Biomed; 2020 Sep; 193():105443. PubMed ID: 32311510
[TBL] [Abstract][Full Text] [Related]
47. A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
Chamberlain MC; Chalmers L
J Neurooncol; 2007 Apr; 82(2):207-9. PubMed ID: 17019532
[TBL] [Abstract][Full Text] [Related]
48. Glioblastoma: If this is the "Temozolomide Era" Where is the Evidence?
Perry JR
Can J Neurol Sci; 2014 May; 41(3):301-2. PubMed ID: 24718814
[No Abstract] [Full Text] [Related]
49. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
50. Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Wick A; Kessler T; Elia AEH; Winkler F; Batchelor TT; Platten M; Wick W
Neuro Oncol; 2018 Jan; 20(2):174-183. PubMed ID: 29016815
[TBL] [Abstract][Full Text] [Related]
51. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
[TBL] [Abstract][Full Text] [Related]
52. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
53. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
54. Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.
Chen TC; Wang W; Golden EB; Thomas S; Sivakumar W; Hofman FM; Louie SG; Schönthal AH
Cancer Lett; 2011 Mar; 302(2):100-8. PubMed ID: 21257259
[TBL] [Abstract][Full Text] [Related]
55. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
56. Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Poelen J; Prick MJ; Jeuken JW; Wesseling P; Bernsen HJ
Acta Neurol Belg; 2009 Sep; 109(3):238-42. PubMed ID: 19902821
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
59. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
[TBL] [Abstract][Full Text] [Related]
60. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
